Professor Adam Cribbs, CTO and co-founder of Entelo Bio, and a group leader in Oxford’s Botnar Institute of Musculoskeletal Sciences, as well as a biological co-ordinator for the Human Cell Atlas, commented
Modern computational biology involves considerable effort in repetitive data processing, tool evaluation, and debugging—tasks critical yet not directly value-adding. Flow Agent1 addresses these issues effectively, enabling our scientists to shift focus toward exploring meaningful biological insights and accelerating therapeutic discovery.
In the wider field, there are now a growing number of companies seeking to accelerate science via similar approaches often under the banner of an “AI scientist”. These include Lilla Sciences, Sakana AI, Future House and Google.
Dr Peter Crane, CEO and co-founder of Entelo Bio said
While the short-term excitement around AI-driven tools is notable, the longer-term impact on how science is conducted remains underestimated. The shift toward services-as-software will improve platform capital efficiency, empowering smaller, AI-native teams to concentrate on genuine scientific innovation rather than repetitive infrastructure tasks.
1 FlowAgent: A Modular Agent-Based System for Automated Workflow Management and Data Interpretation. Joshua Philpott, Alina Kurjan, Adam Cribbs bioRxiv 2025.03.06.641728; doi: https://doi.org/10.1101/2025.03.06.641728
About Entelo Bio
Entelo Bio is a biotechnology company decoding complex diseases with unmatched resolution to develop new precision medicines. Founded at the intersection of proprietary approaches to isoform discovery and machine learning, their platform reveals hidden causative biology, enabling the development of new precision medicines. The company was founded based on foundational work from Oxford University’s Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences and has been published in journals such as Nature Biotechnology, Nature Methods and Nature Reviews Rheumatology.